109 related articles for article (PubMed ID: 15736296)
1. Multiple myeloma.
Schneider HG; Sentry J
N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15736296
[No Abstract] [Full Text] [Related]
2. Evidence of a role for RANKL in the development of myeloma bone disease.
De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
[TBL] [Abstract][Full Text] [Related]
3. RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation.
Ashcroft AJ; Carding SR
Gut; 2005 Sep; 54(9):1345-6. PubMed ID: 16099805
[No Abstract] [Full Text] [Related]
4. Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification.
Al-Fakhri N; Hofbauer LC; Preissner KT; Franke FE; Schoppet M
Thromb Haemost; 2005 Dec; 94(6):1335-7. PubMed ID: 16411417
[No Abstract] [Full Text] [Related]
5. Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3.
Voskaridou E; Terpos E
Eur J Haematol; 2005 Apr; 74(4):359-61. PubMed ID: 15777350
[No Abstract] [Full Text] [Related]
6. The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models.
Neumann E; Gay S; Müller-Ladner U
Arthritis Rheum; 2005 Oct; 52(10):2960-7. PubMed ID: 16200575
[No Abstract] [Full Text] [Related]
7. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.
Hofbauer LC; Heufelder AE; Erben RG
J Rheumatol; 2001 Apr; 28(4):685-7. PubMed ID: 11327234
[No Abstract] [Full Text] [Related]
8. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
9. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
10. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Bone; 2005 May; 36(5):812-9. PubMed ID: 15794927
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
12. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid.
Hofbauer LC; Cepok S; Hemmer B
Acta Neuropathol; 2004 Jun; 107(6):575-7, author reply 578. PubMed ID: 15106011
[No Abstract] [Full Text] [Related]
14. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
[TBL] [Abstract][Full Text] [Related]
15. [Clinical implications of new insights into the regulation of bone resorption].
Lems WF; Bijlsma JW
Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
[TBL] [Abstract][Full Text] [Related]
16. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
Padagas J; Colloton M; Shalhoub V; Kostenuik P; Morony S; Munyakazi L; Guo M; Gianneschi D; Shatzen E; Geng Z; Tan HL; Dunstan C; Lacey D; Martin D
Calcif Tissue Int; 2006 Jan; 78(1):35-44. PubMed ID: 16362459
[TBL] [Abstract][Full Text] [Related]
17. DKK1 in multiple myeloma.
Hofbauer LC; Neubauer A; Schoppet M
N Engl J Med; 2004 Apr; 350(14):1464-6; author reply 1464-6. PubMed ID: 15074002
[No Abstract] [Full Text] [Related]
18. Areca nut extracts modulated expression of alkaline phosphatase and receptor activator of nuclear factor kappaB ligand in osteoblasts.
Ling LJ; Ho FC; Chen YT; Holborow DW; Liu TY; Hung SL
J Clin Periodontol; 2005 Apr; 32(4):353-9. PubMed ID: 15811051
[TBL] [Abstract][Full Text] [Related]
19. DKK1 in multiple myeloma.
Lu CM
N Engl J Med; 2004 Apr; 350(14):1464-6; author reply 1464-6. PubMed ID: 15074001
[No Abstract] [Full Text] [Related]
20. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
